The WNBA, which has long positioned itself as an advocate on social justice issues, announced a partnership Tuesday with the first FDA-approved over-the-counter daily birth control pill. The drug, Opill, fits with the league’s stated focus on reproductive health-care advocacy during the 2024 season.
“At the WNBA, we are committed to addressing issues that matter to the players, and expanding access to reproductive healthcare is one of those key issues,” the league’s chief growth officer Colie Edison said in a statement. “It’s great to be working with a partner whose values align and authentically integrates into the health equity work our players are dedicated to.” Read More
Recent Comments